RxDoctor Payments Data

Youssef Hokayem, MD

Nephrology · Hyattsville, MDNPI 1417185109

Payments from drug & device makers

$791in general payments, 2019–2025

Across 25 payments — averaging $31.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$202
  • Mallinckrodt Enterprises LLC$147
  • GSK$122
  • Mallinckrodt Hospital Products Inc.$111
  • Bard Peripheral Vascular, Inc.$96
  • Akebia Therapeutics Inc$54
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$76096%
  • Education$304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$791 in reported general payments places this provider in the 50th percentile of 285 nephrology providers in Maryland.

See all nephrology providers in Maryland

Medicare billing

Part B allowed, 2024
$398,305
Medicare patients
402
Services billed
2,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol60$88,781
JardianceEmpagliflozin57$76,387
BiktarvyBictegrav/Emtricit/Tenofov Ala16$60,390
VelphoroSucroferric Oxyhydroxide16$46,089
KerendiaFinerenone23$41,211
EliquisApixaban14$16,523
Atovaquone16$11,462
LokelmaSodium Zirconium Cyclosilicate15$9,366
Nifedipine ErNifedipine102$4,027
Calcitriol222$3,775
Sevelamer Carbonate25$3,710
Hydralazine Hcl122$2,627
Calcium Acetate21$1,931
Bumetanide22$1,485
Labetalol Hcl28$1,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$14$98,14675 claims
Fresenius USA Marketing, Inc.Velphoro$15$46,08916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 285 nephrology providers in Maryland.

Other nephrology in Hyattsville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →